Higher frequency of paraoxonase gene polymorphism and cardiovascular impairment among Brazilian Fabry Disease patients

Higher frequency of paraoxonase gene polymorphism and cardiovascular impairment among Brazilian Fabry Disease patients

Author Barris-Oliveira, A. C. Autor UNIFESP Google Scholar
Mueller, K. B. Autor UNIFESP Google Scholar
Turaca, L. T. Autor UNIFESP Google Scholar
Pesquero, J. B. Autor UNIFESP Google Scholar
Martins, A. M. Autor UNIFESP Google Scholar
D'Almeida, V. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Objectives: Paraoxonase (PON1) plays a role in preventing the oxidation of lipoproteins and protecting against atherosclerosis. Several polymorphisms have been described in the gene encoding this enzyme, which are related to different enzymatic activities. Fabry Disease (FD) is a lysosomal storage disease associated with cardiomyopathy, early-onset stroke, renal failure, among other features. the objective of the current study was to investigate the PON1 polymorphisms Gln192Arg and Leu55Met in FD patients and correlate them with clinical symptoms.Design and methods: A total of 106 subjects with FD and 26 healthy individuals were selected for the study. Both polymorphisms were assessed in the DNA of blood samples using PCR-RFLP. Hardy-Weinberg equilibrium was calculated for the genotypes and statistical analyses were realized using the Chi-Squared test with Yates correction.Results: the allele frequencies of the polymorphism Gln192Arg for FD patients and control were 0.38 and 0.25, respectively. A comparison of the frequencies for Gln192Arg polymorphism between FD patients and controls revealed a significant difference. the clinical information was obtained from 41 patients. Patients with the Gln192Arg polymorphism showed different cardiovascular manifestations.Conclusions: the higher frequency of the Gln192Arg polymorphism among FD patients highlighted the possibility of a correlation between the PON1 genetic variation and the phenotypes because the disease has a wide range of symptoms not explained exclusively by mutations on the GLA gene. (C) 2012 the Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Keywords Paraoxonase 1 gene
Genetic polymorphisms
Fabry disease
Cardiovascular outcomes
Language English
Sponsor Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
AFIP
IGEIM
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Date 2012-11-01
Published in Clinical Biochemistry. Oxford: Pergamon-Elsevier B.V., v. 45, n. 16-17, p. 1459-1462, 2012.
ISSN 0009-9120 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 1459-1462
Origin http://dx.doi.org/10.1016/j.clinbiochem.2012.06.034
Access rights Closed access
Type Article
Web of Science ID WOS:000311064200033
URI http://repositorio.unifesp.br/handle/11600/35458

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account